Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prognostic Factors of Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04292964
Recruitment Status : Completed
First Posted : March 3, 2020
Last Update Posted : March 17, 2020
Sponsor:
Information provided by (Responsible Party):
Dongying Zhang, Chongqing Medical University

Brief Summary:
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. Despite lower mortality rate, SARS-CoV-2 has killed more people than SARS and MERS and the number keeps growing. Epidemic studies have been well described clinical features of patients with COVID-19, with the disease severity being an independent predictor of poor outcome. However, there is still no research investigating the prognostic factors of patients with COVID-19.

Condition or disease
SARS-CoV-2 Outcome, Fatal

Layout table for study information
Study Type : Observational
Actual Enrollment : 201 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Prognostic Factors of Patients With COVID-19
Actual Study Start Date : March 1, 2020
Actual Primary Completion Date : March 13, 2020
Actual Study Completion Date : March 13, 2020



Primary Outcome Measures :
  1. all-cause mortality [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. all-cause mortality [ Time Frame: 15 days ]
  2. Severe state [ Time Frame: 15 days ]
    Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with COVID-19
Criteria

Inclusion Criteria:

  • Adult aged >=18years old;
  • Diagnosed with CONVID19. Diagnostic criteria including: Laboratory (RT-PCR) confirmed SARS-Cov-2 infection; CT of the lung conformed to the manifestation of viral pneumonia.
  • Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg.

Exclusion Criteria:

  • Near-death state (expected survival time less than 24 hours);
  • Malignant tumor;
  • Pregnancy or puerperium women;
  • Patients who refused to participant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04292964


Locations
Layout table for location information
China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Sponsors and Collaborators
Chongqing Medical University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dongying Zhang, Clinical Professor, Chongqing Medical University
ClinicalTrials.gov Identifier: NCT04292964    
Other Study ID Numbers: 2020-02-2
First Posted: March 3, 2020    Key Record Dates
Last Update Posted: March 17, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No